These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 22803220)
1. Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement. Jakas J Seton Hall Law Rev; 2012; 42(3):1287-36. PubMed ID: 22803220 [No Abstract] [Full Text] [Related]
2. "Obvious to try": a proper patentability standard in the pharmaceutical arts? Trask AV Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581 [No Abstract] [Full Text] [Related]
3. Science and the law. Working through the patent problem. Walsh JP; Cohen WM; Arora A Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928 [No Abstract] [Full Text] [Related]
4. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech. Garber K Science; 2006 May; 312(5775):827. PubMed ID: 16690824 [No Abstract] [Full Text] [Related]
5. Patent border wars: defining the boundary between scientific discoveries and patentable inventions. Holman CM Trends Biotechnol; 2007 Dec; 25(12):539-43. PubMed ID: 17983675 [TBL] [Abstract][Full Text] [Related]
6. Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching. Mack GS J Natl Cancer Inst; 2006 Aug; 98(15):1028-30. PubMed ID: 16882935 [No Abstract] [Full Text] [Related]
7. Enzo Biochem v. Gen-Probe: complying with the written description requirement under US patent law. Blaug S; Shuster M; Su H Nat Biotechnol; 2003 Jan; 21(1):97-9. PubMed ID: 12511910 [No Abstract] [Full Text] [Related]
8. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
9. Written description. Becker DM Nat Rev Drug Discov; 2004 Oct; 3(10):821. PubMed ID: 15497245 [No Abstract] [Full Text] [Related]
11. Transferring innovation. Kesan JP Fordham Law Rev; 2009 Apr; 77(5):2169-223. PubMed ID: 19431909 [No Abstract] [Full Text] [Related]
12. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
13. The role of the private sector in biotechnology: research and development. Feisee L Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359 [No Abstract] [Full Text] [Related]
14. Sharing information is preferable to patenting. Macilwain C Nature; 2013 Jun; 498(7454):273. PubMed ID: 23783592 [No Abstract] [Full Text] [Related]
15. Proposed changes to patent code loom over biotech industry. Coombs A Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010 [No Abstract] [Full Text] [Related]
16. The importance of patent sharing in neglected disease drug discovery. Edlin C Future Med Chem; 2011 Sep; 3(11):1331-4. PubMed ID: 21879838 [No Abstract] [Full Text] [Related]
17. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
18. Lecture: patents, product exclusivity, and information dissemination: how law directs biopharmaceutical research and development. Eisenberg RS Fordham Law Rev; 2003 Dec; 72(3):477-91. PubMed ID: 14968794 [No Abstract] [Full Text] [Related]